Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model

Invest New Drugs. 2012 Aug;30(4):1743-9. doi: 10.1007/s10637-011-9686-5. Epub 2011 May 18.
No abstract available

MeSH terms

  • Albumins / metabolism*
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Dose-Response Relationship, Drug
  • Doxorubicin / adverse effects
  • Doxorubicin / analogs & derivatives*
  • Doxorubicin / chemistry
  • Doxorubicin / therapeutic use*
  • Female
  • Humans
  • Hydrazones / adverse effects
  • Hydrazones / chemistry
  • Hydrazones / therapeutic use*
  • Mice
  • Mice, Nude
  • Ovarian Neoplasms / drug therapy*
  • Prodrugs / adverse effects
  • Prodrugs / chemistry
  • Prodrugs / therapeutic use*
  • Protein Binding
  • Remission Induction
  • Treatment Outcome
  • Xenograft Model Antitumor Assays*

Substances

  • Albumins
  • Hydrazones
  • Prodrugs
  • Doxorubicin
  • DOXO-EMCH